Affimed N.V. announced interim safety and efficacy data on its innate cell engager (ICE(R) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6(th), 2023, includes 15 patients from the EGFR- wildtype NSCLC cohort with a median of 2 prior lines of therapy. The Company also announced data from the phase 1/2 data study of acimtamig in combination with allogeneic NK in relapsed/refractory Hodgkin Lymphoma patients conducted at the University of Texas MD Anderson Cancer Center.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.03 USD | +3.07% | -2.33% | -19.52% |
Apr. 01 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
Apr. 01 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.52% | 76.59M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients